SCHERING-PLOUGH CLARITIN U.S. FIRST HALF SALES ARE $210 MIL., COMPANY TELLS ANALYSTS; NDAs FOR FARESTON AND CLARITIN ADD ARE PENDING AT FDA
Schering Labs U.S. sales of the nonsedating antihistamine Claritin were $210 mil. in the first half of 1995, according to materials distributed at the Robert W. Baird & Co. 1995 Healthcare Conference Aug. 9 in Chicago.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth